SonoVascular, Inc. Secures $6.

SonoVascular, Inc. has secured $6.0 million in new investment capital from investors.

This funding round marks a significant milestone for the medical device company as it advances its innovative technology for treating blood clots.

The capital infusion will support the continued development and commercialization efforts for its SonoThrombectomy™ System.

SonoVascular is developing the SonoThrombectomy™ System, a novel and differentiated ultrasound-facilitated, thrombolytic-enhanced thrombectomy system.

This technology utilizes microbubble-mediated cavitation as a core mechanical mechanism of action to treat blood clots more safely and effectively.

Designed as a mechanical-pharmaco cathlab-based solution, the system aims to treat patients in a single-session, standalone procedure, offering maximum clot reduction without significant blood loss or vascular trauma.

The $6.0 million investment underscores investor confidence in SonoVascular's approach to clot management.

Initial clinical results suggest the SonoThrombectomy System has the potential to redefine current clinical practices, presenting a transformative alternative to existing incremental innovations.

The newly raised capital will be strategically deployed to accelerate ongoing research and development, expand clinical trials, and prepare for regulatory submissions, bringing the system closer to broader market availability.

This funding positions SonoVascular to further its mission of providing safer and more effective solutions for patients suffering from blood clots.

The company plans to use the funds to scale its operations and continue its trajectory toward becoming a key innovator in the interventional cardiology and radiology fields, ultimately aiming to improve patient outcomes globally.